Controversies in COX-2 selective inhibition.
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. lsimon@caregroup.harvard.edu
Lee S
LS
Simon
Josef S
JS
Smolen
Steven B
SB
Abramson
Gerald
G
Appel
Claire
C
Bombardier
D Craig
DC
Brater
Ferdinand C
FC
Breedveld
K
K
Brune
Gerd R
GR
Burmester
Leslie J
LJ
Crofford
Maxime
M
Dougados
Raymond N
RN
DuBois
Garret A
GA
Fitzgerald
W
W
Frishman
Luis A
LA
García Rodríguez
Marc C
MC
Hochberg
Joachim R
JR
Kalden
Loren
L
Laine
Michael J S
MJ
Langman
Stephen M
SM
Prescott
Leo B A
LB
van de Putte
Andrew
A
Whelton
William B
WB
White
Gordon H
GH
Willaims
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects* / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012680:Sensitivity and Specificity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D001241:Aspirin